BMS 986406
Alternative Names: BMS-986406Latest Information Update: 11 Jul 2022
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 Mar 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (unspecified route) (NCT05298592)
- 31 Mar 2022 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA (unspecified route) (NCT05298592)
- 31 Mar 2022 Bristol-Myers Squibb plans a phase-I trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease, In adults, In the elderly) in USA and Spain (NCT05298592)